Ironwood Pharmaceuticals (NASDAQ:IRWD) Trading 4.5% Higher – Time to Buy?

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)’s share price traded up 4.5% during mid-day trading on Monday . The stock traded as high as $3.70 and last traded at $3.6590. 744,596 shares traded hands during trading, a decline of 71% from the average session volume of 2,581,015 shares. The stock had previously closed at $3.50.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the company. Wall Street Zen upgraded Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Saturday, August 9th. Weiss Ratings reissued a “sell (d)” rating on shares of Ironwood Pharmaceuticals in a research report on Monday, November 24th. Zacks Research lowered shares of Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 4th. Finally, Wells Fargo & Company increased their price target on shares of Ironwood Pharmaceuticals from $1.00 to $3.00 and gave the stock an “equal weight” rating in a research note on Tuesday, November 11th. One analyst has rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Ironwood Pharmaceuticals currently has an average rating of “Hold” and an average target price of $5.34.

Ironwood Pharmaceuticals Stock Performance

The company’s fifty day moving average price is $2.08 and its 200 day moving average price is $1.30. The firm has a market capitalization of $581.58 million, a price-to-earnings ratio of -71.29 and a beta of 0.37.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its earnings results on Monday, November 10th. The biotechnology company reported $0.24 earnings per share for the quarter, beating the consensus estimate of $0.09 by $0.15. Ironwood Pharmaceuticals had a negative return on equity of 2.46% and a negative net margin of 2.25%.The firm had revenue of $122.06 million for the quarter, compared to the consensus estimate of $74.22 million. Ironwood Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, sell-side analysts expect that Ironwood Pharmaceuticals, Inc. will post 0.1 earnings per share for the current year.

Institutional Investors Weigh In On Ironwood Pharmaceuticals

Large investors have recently made changes to their positions in the company. Integrated Wealth Concepts LLC lifted its holdings in Ironwood Pharmaceuticals by 21.4% in the third quarter. Integrated Wealth Concepts LLC now owns 19,295 shares of the biotechnology company’s stock valued at $25,000 after buying an additional 3,406 shares during the period. OVERSEA CHINESE BANKING Corp Ltd bought a new position in shares of Ironwood Pharmaceuticals in the 2nd quarter worth about $25,000. R Squared Ltd lifted its stake in shares of Ironwood Pharmaceuticals by 286.5% in the 2nd quarter. R Squared Ltd now owns 38,765 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 28,735 shares during the period. Focus Partners Advisor Solutions LLC boosted its position in shares of Ironwood Pharmaceuticals by 284.6% during the 2nd quarter. Focus Partners Advisor Solutions LLC now owns 39,743 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 29,409 shares in the last quarter. Finally, Captrust Financial Advisors acquired a new stake in Ironwood Pharmaceuticals during the second quarter worth approximately $32,000.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.